Efficacy of Oral Acetaminophen and Intravenous Chlorpheniramine Maleate versus Placebo to Prevent Red Cell Transfusion Reactions in Children and Adolescent with Thalassemia: A Prospective, Randomized, Double-Blind Controlled Trial

Table 3

Risk factors for development of urticarial rash at 4 to 24 hours post-RBC transfusion.

	Rash 4 - 24 hrs		p-value	Crude OR	95%CI	Adjusted OR	95%CI
	Yes	No
	N = 27	N = 120
Thalassemia types
ß thal/ß thal	5(26.3)	14(73.7)	0.159	3.095	0.643-14.906
ß thal/Hb E	19(19.2)	80(80.8)	0.275	2.058	0.563-7.519
Others	3(10.3)	26(89.7)		1
RBC products
LPRC	19(19.2)	80(80.8)	0.711	1.187	0.478-2.947
LDPRC	8(16.7)	40(83.3)
Age
	13.22±4.58	11.61±4.81	0.118	1.079	0.981-1.187	1.103	0.993-1.225
Gender
Male	10(12.2)	72(87.8)		1		1
Female	17(26.2)	48(73.8)	0.033	2.55	1.077-6.04	2.990	1.204-7.426
Premedications
Active drugs	8(11)	65(89)	0.025	0.356	0.145-0.877	0.263	0.101-0.689
Placebo	19(25.7)	55(74.3)		1		1

Note. Data were shown as number (%), and associated risks between treatment groups were analyzed by binary logistic regression; : p<0.05 is statistically significant.
Abbreviations. ß thal/ß thal: homozygous beta thalassemia; ß thal/HbE: beta thalassemia/hemoglobin E; RBC: red blood cell; LPRC: leukocyte poor packed red cell; LDPRC: leukocyte depleted packed red cell.